Anticoagulation

Anticoagulant Recall:  Incorrect Dose Discovered in Bottle

Anticoagulant Recall: Incorrect Dose Discovered in Bottle

By

Bristol-Myers Squibb is recalling one lot of Eliquis after finding that 1 of the bottles contained the wrong dosage.

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

Effect of Obesity Paradox on Venous Thromboembolism Risk in Atrial Fib

By

A meta-analysis was conducted to examine concerns surrounding direct oral anticoagulant therapy in patients with extreme high or low body weight.

Maternal and Fetal Risk with Anticoagulation in Pregnancy

Maternal and Fetal Risk with Anticoagulation in Pregnancy

Anticoagulation treatment for patients with mechanical heart valves during pregnancy is linked to maternal and fetal risks.

New Model Predicts Gastrointestinal Bleeding in Anticoagulated Patients

New Model Predicts Gastrointestinal Bleeding in Anticoagulated Patients

A new model can help predict acute gastrointestinal bleeding, associated with increased risk of all-cause mortality.

Predicted Risk of Venous Thromboembolism May Warrant Restarting Anticoagulation

Predicted Risk of Venous Thromboembolism May Warrant Restarting Anticoagulation

Treating patients with at least a 17.5% predicted one-year venous thromboembolism risk may cost-effective.

Oral Anticoagulation Treatment Benefits From Electronic-Health-Based Management

Oral Anticoagulation Treatment Benefits From Electronic-Health-Based Management

Fewer adverse events were linked to electronic-health-based management of oral anticoagulation therapy.

Dementia Risk in Atrial Fibrillation Increases With Delayed Anticoagulation

Dementia Risk in Atrial Fibrillation Increases With Delayed Anticoagulation

By

The delayed start of anticoagulation treatment for atrial fibrillation has been linked to an increase risk for dementia.

Newly Diagnosed Atrial Fibrillation Benefits From Rivaroxaban, Dabigatran

Newly Diagnosed Atrial Fibrillation Benefits From Rivaroxaban, Dabigatran

By

Direct oral anticoagulation reduced the risk of congestive heart failure admissions and all-cause mortality in both genders.

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

Uninterrupted Anticoagulation With Dabigatran Improves Atrial Fibrillation Ablation Outcomes, Expert Q&A

By

Incidence of major bleeding events was lower with dabigatran vs warfarin in atrial fibrillation ablation.

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

VTE Recurrence Risk Reduced With Rivaroxaban: Q&A With EINSTEIN CHOICE Investigator

By

Results from the EINSTEIN CHOICE trial plus an interview with investigator Philip Stephen Wells, MD, FRCP(C), MSc.

Anticoagulation Therapy in Patients With Atrial Fibrillation

Anticoagulation Therapy in Patients With Atrial Fibrillation

According to research, many patients with afib who were later diagnosed with acute ischemic stroke may not have been receiving appropriate anticoagulation therapy.

Intracerebral Hemorrhage: Restarting Oral Anticoagulation

Intracerebral Hemorrhage: Restarting Oral Anticoagulation

By

Regardless of intracerebral hemorrhage location, restarting oral anticoagulation is associated with favorable outcomes.

NOACS More Adopted Into Clinical Practice

NOACS More Adopted Into Clinical Practice

Of the 80% of patients prescribed oral anticoagulants, nearly 50% were prescribed non-vitamin K antagonist anticoagulants.

Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision Pathway

Periprocedural Anticoagulation in Atrial Fibrillation: American College of Cardiology Decision Pathway

By

The American College of Cardiology released a decision pathway for managing periprocedural anticoagulation in patients with nonvalvular atrial fibrillation

Atrial Fibrillation Inpatient Costs: Dabigatran, Rivaroxaban, and Warfarin

Atrial Fibrillation Inpatient Costs: Dabigatran, Rivaroxaban, and Warfarin

Compared with warfarin, inpatient costs for newly diagnosed atrial fibrillation were lower for dabigatran and rivaroxaban.

Oral Anticoagulant Therapy Use in Older Stroke Surivors

Oral Anticoagulant Therapy Use in Older Stroke Surivors

Almost half of the patients were not prescribed an oral anticoagulant despite a median CHA2DS2VASc score of 5.

Continuing Warfarin in Nonvalvular Atrial Fibrillation With Dementia

Continuing Warfarin in Nonvalvular Atrial Fibrillation With Dementia

Continuing wafarin after a diagnosis of dementia appears to have a protective effect in prevention of ischemic stroke, major bleeding, and all-cause mortality.

Proton Pump Inhibitors With Warfarin Reduces GI Bleeding

Proton Pump Inhibitors With Warfarin Reduces GI Bleeding

Patients who received proton pump inhibitor co-therapy when beginning warfarin had a 24% decreased risk for upper gastrointestinal bleeding.

Recurrence of Atrial Fibrillation, Stroke After Ablation

Recurrence of Atrial Fibrillation, Stroke After Ablation

In patients with an event-free period of at least 12 months after atrial fibrillation ablation, risk of stroke or recurrent atrial fibrillation is low.

Off-Label Dosing of NOACs in Atrial Fibrillation Is a Concern

Off-Label Dosing of NOACs in Atrial Fibrillation Is a Concern

By

About 1 in 8 patients in the ORBIT-AF II registry were given "off-label" non-vitamin K antagonist doses.

Sleep Apnea Increases Risk of Recurrent Pulmonary Embolism

Sleep Apnea Increases Risk of Recurrent Pulmonary Embolism

Obstructive sleep apnea is an independent risk factor for recurrent pulmonary embolism in patients who stop taking oral anticoagulation for a first episode.

Intracranial Hemorrhage Risk Increased with Selective Serotonin Reuptake Inhibitors

Intracranial Hemorrhage Risk Increased with Selective Serotonin Reuptake Inhibitors

By

Relative to tricyclic antidepressants, SSRIs were associated with an increased risk for intracranial hemorrhage.

Dangers of Anticoagulation Discontinuation in Atrial Fibrillation After PVI

Dangers of Anticoagulation Discontinuation in Atrial Fibrillation After PVI

By

Patients with a CHA2DS2-VASc score of 2 or more who discontinued warfarin had higher rates of stroke than those who continued treatment.

Main Cause of Mortality in Anticoagulated Atrial Fibrillation

Main Cause of Mortality in Anticoagulated Atrial Fibrillation

By

Cardiac-related death is the main cause of mortality among patients with atrial fibrillation on anticoagulants.

Heparin Does Not Prevent Venous Thromboembolism in Knee Arthroscopy

Heparin Does Not Prevent Venous Thromboembolism in Knee Arthroscopy

Venous thromboembolism occurred in 1.4% of the treatment group and 1.8% of the control group.

Restarting Anticogulation Therapy After a Major Bleeding Event

Restarting Anticogulation Therapy After a Major Bleeding Event

Patients taking dabigatran after their bleeding event were nearly half as likely to have another major bleeding event within 1 year compared to those who took warfarin.

Trans-esophageal Echocardiography Trends in Atrial Fibrillation Ablation

Trans-esophageal Echocardiography Trends in Atrial Fibrillation Ablation

By

Pre-ablation trans-esophageal echocardiography rates dropped from 86% to 42%; meanwhile, cerebrovascular accidents occurred in only 0.40% of patients.

Adverse Drug Events for Anticoagulants, Diabetes Agents Have Increased

Adverse Drug Events for Anticoagulants, Diabetes Agents Have Increased

There were an estimated 4 emergency department visits per 1000 individuals annually in 2013 and 2014; 46.9% of which were related to anticoagulants, diabetes agents, and antibiotics.

Probable Drug Interaction Between Warfarin and Hepatitis C Therapy

Probable Drug Interaction Between Warfarin and Hepatitis C Therapy

According to a case study, a patient's INR for warfarin became critically supratherapeutic about 2 weeks after direct-acting antiviral therapy was completed and discontinued.

FDA Approves Device for Stroke Involving Patent Foramen Ovale

FDA Approves Device for Stroke Involving Patent Foramen Ovale

Patients who used the device plus anticoagulants were 50% less likely to have a new stroke, compared to those who took anticoagulants alone.

Sign Up for Free e-Newsletters